The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 16, 2026

Filed:

Mar. 24, 2021
Applicants:

Shenzhen Chipscreen Biosciences Co., Ltd., Shenzhen, CN;

Chengdu Chipscreen Pharmaceutical Co., Ltd, Sichuan, CN;

Inventors:

Xianping Lu, Shenzhen, CN;

Zhiqiang Ning, Shenzhen, CN;

Xiaoning Wang, Shenzhen, CN;

Attorneys:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/47 (2006.01); A61K 9/48 (2006.01); A61K 31/337 (2006.01); A61K 31/7048 (2006.01); A61P 15/08 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
A61K 31/47 (2013.01); A61K 9/48 (2013.01); A61K 31/337 (2013.01); A61K 31/7048 (2013.01); A61P 15/08 (2018.01); A61P 35/00 (2018.01);
Abstract

The present invention relates to the field of biotechnology, and in particular relates to a pharmaceutical composition comprising a protein kinase inhibitor and a chemotherapeutic drug and use thereof. It is found that in the treatment of platinum-refractory/drug-resistant relapsed advanced ovarian cancer, the remission rates of etoposide or paclitaxel in combination with chiauranib is respectively 40% and 50%, while the remission rate of etoposide alone is about 27%, and the remission rate of paclitaxel alone is about 21%, indicating that the combination of chiauranib and etoposide or paclitaxel in the treatment of platinum-refractory/drug-resistant relapsed advanced ovarian cancer has achieved unexpected synergistic effects.


Find Patent Forward Citations

Loading…